Clinical Trial for Metastatic Colorectal Cancer (CRDF-004)
Patients and Caregivers
Cancer patients have important goals when managing their condition, which may include participation in a clinical trial with an investigational drug.
On this page, you will find resources which may be useful to you.
For more information about Cardiff Oncology’s ongoing clinical trial in metastatic colorectal cancer, please visit the CRDF-004 clinical trial website on ClinicalTrials.gov, or contact us via email at [email protected].
Please do not include any personal health information or reports/scans if submitting inquiries to [email protected].
Cardiff Oncology’s clinical trial for metastatic colorectal cancer (CRDF-004)
How do I know if I can take part?
You may be able to take part in our CRDF-004 clinical trial if:
- You have been diagnosed with metastatic colorectal cancer.
- The cancer cells have a specific genetic mutation known as a RAS mutation. There are several types of RAS mutations including KRAS and NRAS that are eligible for enrollment in our trial.
- You have not had previous systemic therapy, such as chemotherapy, in the metastatic setting.
- You can discuss your eligibility for the CRDF-004 trial with your healthcare provider. The complete list of Key eligibility criteria are listed on the CRDF-004 clinical trial website on ClinicalTrials.gov.